Fulcrum Therapeutics (FULC) Enterprise Value (2019 - 2025)
Historic Enterprise Value for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to -$200.6 million.
- Fulcrum Therapeutics' Enterprise Value fell 17625.64% to -$200.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$200.6 million, marking a year-over-year decrease of 17625.64%. This contributed to the annual value of -$241.0 million for FY2024, which is 203.2% down from last year.
- According to the latest figures from Q3 2025, Fulcrum Therapeutics' Enterprise Value is -$200.6 million, which was down 17625.64% from -$214.1 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Enterprise Value ranged from a high of -$30.1 million in Q3 2023 and a low of -$241.0 million during Q4 2024
- Its 5-year average for Enterprise Value is -$98.7 million, with a median of -$65.5 million in 2021.
- As far as peak fluctuations go, Fulcrum Therapeutics' Enterprise Value skyrocketed by 6693.33% in 2022, and later plummeted by 57303.27% in 2023.
- Quarter analysis of 5 years shows Fulcrum Therapeutics' Enterprise Value stood at -$35.4 million in 2021, then rose by 0.89% to -$35.1 million in 2022, then plummeted by 573.03% to -$236.2 million in 2023, then fell by 2.03% to -$241.0 million in 2024, then increased by 16.75% to -$200.6 million in 2025.
- Its last three reported values are -$200.6 million in Q3 2025, -$214.1 million for Q2 2025, and -$226.6 million during Q1 2025.